Takaishi, Hiromasa

写真a

Affiliation

School of Medicine, Center for Preventive Medicine (Shinanomachi)

Position

Professor

External Links

Career 【 Display / hide

  • 2002.10
    -
    2007.03

    慶應義塾大学医学部, 包括先進医療センター, 助手

  • 2007.04
    -
    2008.03

    慶應義塾大学医学部, 包括医療先進センター, 助教

  • 2008.04
    -
    2009.03

    慶應義塾大学医学部, 包括医療先進センター, 学部内講師

  • 2009.07
    -
    2013.05

    慶應義塾大学医学部, 腫瘍センター, 専任講師

  • 2009.10
    -
    2017.09

    慶應義塾大学医学部, 腫瘍センター, 副センター長

display all >>

Academic Background 【 Display / hide

  • 1990.03

    慶應義塾大学, 医学部, 医学科

    University, Graduated

  • 1996.03

    慶應義塾大学, 医学研究科, 内科学

    Withdrawal after completion of doctoral course requirements, Doctoral course

Academic Degrees 【 Display / hide

  • 博士(医学), 慶應義塾大学, 2000.02

    潰瘍性大腸炎における大腸杯細胞内ムチンに対する自己抗体とその病的意義の検討

Licenses and Qualifications 【 Display / hide

  • 医師免許証, 1990.06

  • 日本内科学会 認定内科医, 1995.09

  • 日本消化器病学会 専門医, 1995.12

  • 日本臨床腫瘍学会がん薬物療法 専門医, 2007.04

  • 日本がん治療認定医機構がん治療 認定医, 2008.04

display all >>

 

Research Areas 【 Display / hide

  • Gastroenterology

Research Keywords 【 Display / hide

  • Cancer Genome Medicine

  • Medical Oncology

 

Books 【 Display / hide

  • オンコロジークリニカルガイド 消化器癌化学療法

    高石官均, 南山堂, 2014

    Scope: 83-87

  • 潰瘍性大腸炎・クローン病

    日比紀文、高石官均, プロバイオティクス・プレバイオティクス・バイオジェニックス, 2006

    Scope: 244-247

  • Crohn 病治療の進歩

    日比紀文、高石官均, 最新内科学大系 プログレス, 1997

    Scope: 8: 310-319

  • Magnifying endoscopic and immunohistochemical study of the colonic minute lesions in inflammatory bowel disease. Current topics on mucosal immunology 1993.

    Inoue N, Hibi T, Takaishi H, Ueno Y, Hayashi A, Hosoda Y, Iwao Y, Watanabe N, Watanabe M, Aiso S, Tsuchiya M, Excerpta Medica, 1994

    Scope: 219-222

  • Autoantibodies in ulcerative colitis and Crohn's disease. Current Topics in Mucosal Immunology

    Hibi T, Ohara H, Takaishi H, Inoue N, Ueno Y, Iwao Y, Watanabe M, Kobayashi K, Aiso S, Tsuchiya M, Excerpta Medica, 1994

    Scope: 155-160

Papers 【 Display / hide

  • Post-progression survival following second-line chemotherapy in patients with advanced pancreatic cancer previously treated with gemcitabine: a meta-analysis

    Kasuga, Akiyoshi, Hamamoto, Yasuo, Takeuchi, Ayano, Okano, Naohiro, Togasaki, Kazuhiro, Aoki, Yu, Suzuki, Takeshi, Kawasaki, Kenta, Hirata, Kenro, Sukawa, Yasutaka, Kanai, Takanori, Takaishi, Hiromasa

    INVESTIGATIONAL NEW DRUGS (Investigational New Drugs)  36 ( 5 ) 939 - 948 2018.10

    Research paper (scientific journal),  ISSN  0167-6997

     View Summary

    © 2018, Springer Science+Business Media, LLC, part of Springer Nature. Background Post-progression survival (PPS) could be a confounding element in interpreting data from clinical trials of second-line chemotherapy in patients with advanced pancreatic cancer (PC) previously treated with gemcitabine (GEM) because a recent meta-analysis of oxaliplatin combination therapy showed statistical heterogeneity for overall survival (OS) but not for progression-free survival (PFS). This study aimed to improve the understanding of the impact of PPS on OS in this setting. Methods Databases were searched to identify randomized controlled trials (RCTs) in the salvage setting. We evaluated relationships between OS and PFS, PPS, and other variables. Results Totally, 17 RCTs with 3253 patients were identified. Median OS was strongly and moderately associated with median PPS and PFS, respectively (r = 0.913; p < 0.001 and 0.780; p < 0.001, respectively). The proportion of patients with good performance status was significantly associated with both PPS and PFS (r = 0.574, p < 0.001 and 0.492, p < 0.001, respectively). The induction rate of subsequent chemotherapy was related to the duration of PPS and OS (r = 0.640, p < 0.001 and 0.647, p < 0.001, respectively). Median PPS and OS were significantly longer in recent trials than those in older trials (3.55 versus 2.78 months, p < 0.001 and 6.29 versus 5.02 months, p < 0.001). Conclusions Median PPS was strongly correlated with median OS. Given the recently increased opportunity for subsequent chemotherapy and supportive care, PPS may serve as an important element to clarify problems in this setting.

  • Pancreatic Fat Content Detected by Computed Tomography and Its Significant Relationship With Intraductal Papillary Mucinous Neoplasm

    Kashiwagi, Kazuhiro, Seino, Takashi, Fukuhara, Seiichirou, Minami, Kazuhiro, Horibe, Masayasu, Iwasaki, Eisuke, Takaishi, Hiromasa, Itoh, Kazunari, Sugino, Yoshinori, Inoue, Nagamu, Iwao, Yasushi, Kanai, Takanori

    PANCREAS (Pancreas)  47 ( 9 ) 1087 - 1092 2018.10

    Research paper (scientific journal),  ISSN  0885-3177

     View Summary

    © Wolters Kluwer Health, Inc. All rights reserved. Objectives Intraductal papillary mucinous neoplasms (IPMNs) are premalignant lesions of pancreatic ductal adenocarcinomas (PDACs). Fat accumulation in the pancreas is increasingly recognized as a cause of PDAC. We aimed to identify factors that are relevant between IPMN and metabolic-related factors, including pancreatic fat. Methods The database for 781 subjects who underwent a health checkup and upper abdominal magnetic resonance imaging was searched and computed tomography attenuation indexes (pancreatic and spleen attenuation, pancreas-to-spleen attenuation ratio) were decided by measuring the regions of interest in the pancreas and spleen on nonenhanced images, using Hounsfield units. Eighty-five subjects from each of the IPMN and noncyst groups were matched for age, sex, and glycemic status and statistically compared in clinical characteristics. Results There was no difference in metabolic-related factors except for apolipoprotein A1 and high-density lipoprotein cholesterol between the 2 groups in univariate analysis. Multivariate logistic regression analysis showed that both indexes were significantly associated with IPMN (odds ratio, 0.905 [95% confidence intervals, 0.851-0.963; P = 0.002]; odds ratio, 0.006 [95% confidence intervals, 0.000-0.152; P = 0.002]). Conclusions Pancreatic fat content measured by computed tomography was significantly associated with IPMN. These results suggest that IPMN may develop secondary to pancreatic steatosis that could be an overlapping risk factor for PDAC and IPMN.

  • Pilot study of WT1 peptide-pulsed dendritic cell vaccination with docetaxel in esophageal cancer

    Matsuda, Tatsuo, Takeuchi, Hiroya, Sakurai, Toshiharu, Mayanagi, Shuhei, Booka, Eisuke, Fujita, Tomonobu, Higuchi, Hajime, Taguchi, Junichi, Hamamoto, Yasuo, Takaishi, Hiromasa, Kawakubo, Hirofumi, Okamoto, Masato, Sunamura, Makoto, Kawakami, Yutaka, Kitagawa, Yuko

    ONCOLOGY LETTERS (Oncology Letters)  16 ( 1 ) 1348 - 1356 2018.07

    Research paper (scientific journal),  ISSN  1792-1074

     View Summary

    © 2018, Spandidos Publications. All rights reserved. In the present study, the immune response to Wilms tumor gene 1 (WT1) peptide-pulsed dendritic cell (DC) vaccination combined with docetaxel (DCDOC) in advanced esophageal cancer patients who had already received first-line chemotherapy was investigated. Ten HLA-A*2402 patients were treated with docetaxel (50 mg/m2) on day 1 and WT1 peptide-pulsed DC vaccination (1x107 cells) on days 15 and 22 (repeated every 4 weeks for 3 cycles). The delayed-type hypersensitivity skin test, HLA tetramer assay and interferon-γ enzyme-linked immunospot (ELISPOT) assay were used to evaluate the induction of a WT1-specific immune response. Median overall survival was 5 months (range, 1.1-11.6). The clinical effect of DCDOC therapy was not observed and only 1 patient could complete the protocol therapy. Disease progression was observed in 9 patients and 1 patient succumbed to fatality during the second cycle of therapy. As a pilot study, it was not possible to evaluate the safety of WT1 peptide-pulsed DCDOC therapy for esophageal squamous cell cancer. However, a WT1-specific response in 6 patients, as indicated by the ELISPOT or HLA/WT1-tetramer assay, was demonstrated. The results suggested that the positive immune response had significant relevance on the low percentage of CD11b+ and CD66b+ granulocytic myeloid-derived suppressor cells in CD15+ cells. Furthermore, DCDOC elicited a WT1-specific immune response regardless of the myelosuppression associated with docetaxel. The present findings support future studies and further work to assess DCDOC as an adjuvant therapy for esophageal cancer will be performed. The present clinical trial was registered in the University Hospital Medical Information Network (UMIN) Clinical Trials Registry on November 11th, 2011, no. UMIN000006704.

  • Guidelines for treatment of renal injury during cancer chemotherapy 2016

    Horie, Shigeo, Oya, Mototsugu, Nangaku, Masaomi, Yasuda, Yoshinari, Komatsu, Yasuhiro, Yanagita, Motoko, Kitagawa, Yuko, Kuwano, Hiroyuki, Nishiyama, Hiroyuki, Ishioka, Chikashi, Takaishi, Hiromasa, Shimodaira, Hideki, Mogi, Akira, Ando, Yuichi, Matsumoto, Koji, Kadowaki, Daisuke, Muto, Satoru

    CLINICAL AND EXPERIMENTAL NEPHROLOGY (Clinical and Experimental Nephrology)  22 ( 1 ) 210 - 244 2018.02

    Research paper (scientific journal),  ISSN  1342-1751

  • Clinical efficacy of immune checkpoint inhibitors in the treatment of unresectable advanced or recurrent gastric cancer: An evidence-based review of therapies

    Togasaki K., Sukawa Y., Kanai T., Takaishi H.

    OncoTargets and Therapy (OncoTargets and Therapy)  11   8239 - 8250 2018

     View Summary

    © 2018 Togasaki et al. Standard treatment options for patients with advanced gastric cancer (GC) offer limited efficacy and are associated with some toxicity, which necessitates the development of more effective therapies for improving the treatment outcomes for this disease. Immunotherapy involving immune checkpoint inhibitors (ICIs) which inhibit the programmed death 1 (PD-1)/ programmed death ligand 1 interaction has emerged as a new treatment option. Nivolumab, a human IgG4 monoclonal antibody inhibitor of PD-1, has demonstrated promising clinical activity and induced durable responses in patients with advanced GC. Nivolumab has recently been approved for treating patients with pretreated advanced GC in Japan. In the present review, we summarized current evidence of the clinical efficacy of ICIs in a variety of solid tumors and reported our experience in patients with GC who were treated with nivolumab and the interesting features that were observed in these cases. Certain ICI-specific clinical features such as pseudo-and hyper-progression of tumor and hyper-response to subsequent chemotherapy have been reported in several cancer types. Lastly, we discussed the present scenario regarding research on biomarkers for assessing the clinical benefits of ICI therapies.

display all >>

Papers, etc., Registered in KOARA 【 Display / hide

Presentations 【 Display / hide

  • Racl Activation Promotes Invasive Phentype of Side Population in Cancer Cells by Destalizing the E-cadherin-βcatenin Ligation.

    TAKAISHI HIROMASA

    The 8th international symposium on cancer research and therapy., 2012.11

  • 切除不能胃癌に対するPaclitaxel、CDDP、S-1併用化学療法の臨床第Ⅰ相試験(KOGC-02)

    TAKAISHI HIROMASA

    第50回日本癌治療学会学術集会, 2012.10

  • 外来がん化学療法における副作用マネジメントシステムの構築と実践-カペシタビンによる手足症候群対策-

    TAKAISHI HIROMASA

    第10回日本臨床腫瘍学会学術総会, 2012.07

  • HER2陽性胃癌のセカンドライン治療をどう行うか

    TAKAISHI HIROMASA

    第10回日本臨床腫瘍学会学術総会, 2012.07

  • PEM+CDDPによる全身化学療法が著効した作成腹膜中皮腫の一例

    TAKAISHI HIROMASA

    第319回日本消化器病学会関東支部例会, 2012.05

display all >>

Research Projects of Competitive Funds, etc. 【 Display / hide

  • 膵胆道癌細胞における抗アポトーシス遺伝子発現調整機構の解析と分子標的治療への応用

    2006
    -
    2007

    基盤研究(C), Grant-in-Aid for Scientific Research

  • 膵癌細胞における上皮由来増殖因子シグナルの解析とアポトーシス抵抗性機序の解明

    2006
    -
    2007

    基盤研究(C), Grant-in-Aid for Scientific Research

  • 消化器癌における癌幹細胞の同定、分離および生物学的特性の解析

    2008
    -
    2010

    基盤研究(C), Grant-in-Aid for Scientific Research

  • プロテオミクス解析およびパスウェイ解析による新規胃癌バイオマーカーの検討

    2014
    -
    2016

    基盤研究(C), Grant-in-Aid for Scientific Research

  • 3D オルガノイド法を用いたがんゲノム個別化医療スクリーニングシステムの開発

    2019.04
    -
    2022.03

    MEXT,JSPS, Grant-in-Aid for Scientific Research, 高石 官均, Grant-in-Aid for Scientific Research (C), Principal Investigator

Awards 【 Display / hide

  • 第26回日本消化器病学会奨励賞

    2012

  • 第14回日本消化器病学会奨励賞

    2001

 

Courses Taught 【 Display / hide

  • LECTURE SERIES, INTERNAL MEDICINE (GASTROENTEROLOGY)

    2019

Courses Previously Taught 【 Display / hide

  • 臨床腫瘍

    Keio University, 2018

  • 消化器内科

    Keio University, 2018

Educational Activities and Special Notes 【 Display / hide

  • 基礎診断学「消化器」下部消化管の腫瘍性疾患 各論「消化器」消化器悪性腫瘍の化学療法

    2006
    -
    Present

    , Device of Educational Contents

  • 学生症例検討クルズス担当

    2006
    -
    Present

    , Device of Educational Contents

  • 慶應義塾大学病院看護部・がん化学療法講習会

    2006.09

    , Lecture at Education Method and Practice

  • 慶應義塾大学21世紀COEプログラム 研究会報告「がん治療認定医制度をめぐって」

    2007.04

    , Device of Educational Contents

  • 慶應義塾大学病院看護部・がん看護研修 第1回総論

    2008
    -
    2011

    , Device of Educational Contents

display all >>

 

Memberships in Academic Societies 【 Display / hide

  • 日本内科学会

     
  • 日本消化器病学会

     
  • 日本消化器内視鏡学会

     
  • 日本癌学会

     
  • 日本癌治療学会

     

display all >>

Committee Experiences 【 Display / hide

  • 2002.04

    リサーチレジメント, 厚生労働省

  • 2008
    -
    Present

    がん登録部会委員, 東京都がん診療連携協議会

  • 2008
    -
    Present

    研修部会委員, 東京都がん診療連携協議会

  • 2008
    -
    Present

    クリティカルパス部会委員, 東京都がん診療連携協議会

  • 2008
    -
    Present

    相談・情報部会委員, 東京都がん診療連携協議会

display all >>